Patents Represented by Attorney, Agent or Law Firm Edward F. Rehberg
-
Patent number: 7037695Abstract: The present invention relates to a method of assaying modulators of the interaction between Wolframin protein and its identified cellular binding partner.Type: GrantFiled: January 30, 2002Date of Patent: May 2, 2006Assignee: Pharmacia & UpjohnInventor: Ronald R. Hiebsch
-
Patent number: 6818413Abstract: The invention relates to novel fluorescence-based assays for protein kinases and phosphatases which can be used in high throughput screening. The methods of the invention utilize a competitive immunoassay to determine the amount of substrate that is phosphorylated or dephosphorylated during the course of a kinase or phosphatase reaction to yield a product, as well as the phosphorylating or dephosphorylating activity of a kinase or phosphatase.Type: GrantFiled: June 20, 2003Date of Patent: November 16, 2004Assignee: Pharmacia and Upjohn CompanyInventors: Dennis E. Epps, Charles K. Marschke
-
Patent number: 6814971Abstract: The invention relates to adjuvants that contain a lecithin, an oil and an amphiphilic surfactant and that are capable of forming a stable oil-in-water emulsion vaccine so as to minimize local reactions to the vaccine in the injected animal.Type: GrantFiled: March 13, 2003Date of Patent: November 9, 2004Assignee: Pfizer Inc.Inventors: David S. Roberts, Leroy A. Swearingin, Don A. Dearwester
-
Patent number: 6734005Abstract: The present invention provides genes encoding novel matrix metalloproteinases termed MMP; constructs and recombinant host cells incorporating the genes; the MMP polypeptides encoded by the genes; antibodies to the MMP polypeptides; and methods of making and using all of the foregoing.Type: GrantFiled: May 22, 2001Date of Patent: May 11, 2004Assignee: Pharmacia & Upjohn CompanyInventors: Timothy Wood, Jonas Ekblom, Erik Holmgren, Mats Kihlén
-
Patent number: 6730778Abstract: The present invention provides isolated nucleic acid molecules comprising a polynucleotide encoding either of two alternative splice variants of human sel-10, one of which is expressed in hippocampal cells, and one of which is expressed in mammary cells. The invention also provides isolated sel-10 polypeptides and cell lines which express them in which A&bgr; processing is altered.Type: GrantFiled: June 9, 1999Date of Patent: May 4, 2004Assignee: Pharmacia and Upjohn CompanyInventors: Mark E. Gurney, Adele M. Pauley, Jinhe Li
-
Patent number: 6706485Abstract: The present invention provides methods of identifying agents that inhibit the amyloid precursor protein (APP) processing activity of Asp2 polypeptide.Type: GrantFiled: April 12, 2000Date of Patent: March 16, 2004Assignee: Pharmacia & Upjohn CompanyInventors: Mark E. Gurney, Michael J. Bienkowski, Robert L. Heinrikson, Luis A. Parodi, Riqiang Yan
-
Patent number: 6693172Abstract: The invention relates to a novel methods for measuring cellular ion channel transmission and methods and compositions useful in the identification of ligand gated ion channel agonists and modulators.Type: GrantFiled: May 25, 2000Date of Patent: February 17, 2004Assignee: Pharmacia and Upjohn CompanyInventors: Vincent E. Groppi, Jr., Mark L. Wolfe, Mitchell B. Berkenpas
-
Patent number: 6686449Abstract: The present invention provides mutant presenilin 1 and presenilin 2 polpeptides and polynucleotides encoding the polypeptides and methods for their production by recombinant and PCR techniques are disclosed. Methods for utilizing the mutant polypeptides in screens for inhibitors of activity are also disclosed.Type: GrantFiled: June 29, 2001Date of Patent: February 3, 2004Assignee: Pharmacia & Upjohn CompanyInventors: Donald Bainbridge Carter, Alfredo Giuseppe Tomasselli
-
Patent number: 6656470Abstract: The invention provides a vaccine composition and a method of preparation including the steps of: forming a water-in-oil emulsion including an alginate in water, an oil, an antigen, and either (a) a cellulose ether and at least one nonionic surfactant or (b) a PEO-PPO-PEO triblock copolymer surfactant and at least one nonionic surfactant; followed by crosslinking the alginate in the emulsion with at least two cations selected from the group consisting of aluminum, barium, calcium, lithium, manganese, strontium, and zinc, to form antigen-containing, crosslinked alginate microparticles; and harvesting the microparticles. Another aspect of the invention is a method of vaccinating a vertebrate species including the step of administering to the species a vaccine composition prepared according to the method of the invention.Type: GrantFiled: May 11, 2001Date of Patent: December 2, 2003Assignee: Pharmacia & Upjohn CompanyInventors: Terry L. Bowersock, Paul Guimond, Tzu-Chi R. Ju, Argaw Kidane
-
Patent number: 6638731Abstract: The present invention provides isolated nucleic acid molecules comprising a polynucleotide encoding either of two alternative splice variants of human sel-10, one of which is expressed in hippocampal cells, and one of which is expressed in mammary cells. The invention also provides isolated sel-10 polypeptides and cell lines which express them in which A&bgr; processing is altered.Type: GrantFiled: December 17, 1998Date of Patent: October 28, 2003Assignee: Pharmacia and Upjohn CompanyInventors: Mark E. Gurney, Adele M. Pauley, Jinhe Li
-
Patent number: 6632621Abstract: The invention provides neuropeptide ligands, G protein-coupled receptors and methods of screening for modulators of receptor activity. Identified modulators, including neuropeptide ligand mimetics, are useful as biostatic and biocidal agents of varying scope, ranging from lethal activity restricted to particular invertebrate parasites to broad spectrum invertebrate parasiticides active on a wide range of invertebrates, including helminths and insects.Type: GrantFiled: November 24, 2000Date of Patent: October 14, 2003Assignee: Pharmacia & Upjohn CompanyInventors: David E. Lowery, Timothy G. Geary, Teresa M. Kubiak, Martha J. Larsen
-
Patent number: 6630311Abstract: The invention relates to novel fluorescence-based assays for protein kinases and phosphatases which can be used in high throughput screening. The methods of the invention utilize a competitive immunoassay to determine the amount of substrate that is phosphorylated or dephosphorylated during the course of a kinase or phosphatase reaction to yield a product, as well as the phosphorylating or dephosphorylating activity of a kinase or phosphatase.Type: GrantFiled: December 6, 2000Date of Patent: October 7, 2003Assignee: Pharmacia & Upjohn CompanyInventors: Dennis E. Epps, Charles K. Marschke
-
Patent number: 6440694Abstract: The invention relates to a novel tumor necrosis factor (TNF) homolog designated herein as TNF-related death ligand (TRDL). Isolated nucleic acid molecules are provided which encode TRDL. TRDL polypeptides are also provided, as are methods for identifying agonists and antagonists of TRDL activity.Type: GrantFiled: September 21, 1998Date of Patent: August 27, 2002Assignee: Pharmacia & Upjohn CompanyInventors: Michael J. Bienkowski, Cynthia J. Mills, David A. Jones
-
Patent number: 6387643Abstract: The present invention provides isolated human heparanase polypeptides, and the isolated polynucleotide molecules that encode them, as well as vectors and host cells comprising such polynucleotide molecules. The invention also provides a method for the identification of an agent that alters heparanase activity.Type: GrantFiled: February 18, 1999Date of Patent: May 14, 2002Assignee: Pharmacia and Upjohn CompanyInventors: Robert Leroy Heinrikson, Michael B. Fairbanks, Ana M. Mildner
-
Patent number: 6203994Abstract: The invention relates to novel fluorescence-based assays for protein kinases and phosphatases which can be used in high throughput screening. The methods of the invention utilize a competitive immunoassay to determine the amount of substrate that is phosphorylated or dephosphorylated during the course of a kinase or phosphatase reaction to yield a product, as well as the phosphorylating or dephosphorylating activity of a kinase or phosphatase.Type: GrantFiled: December 2, 1998Date of Patent: March 20, 2001Assignee: Pharmacia & Upjohn CompanyInventors: Dennis E. Epps, Charles K. Marschke
-
Patent number: 6187552Abstract: The invention provides a method of identifying a therapeutic useful for treating or preventing asthma, which method includes the steps of contacting a identify compounds that inhibit the binding of human JAK2 protein to the &bgr;c first molecule comprising at least the N terminal 294 residues of JAK2 protein as shown in SEQ ID NO: 5 with a second molecule comprising at least 13 membrane proximal cytoplasmic amino acid residues of the &bgr;c subunit of the IL-3, IL-5, and GM-CSF receptors as shown in SEQ ID NO: 3 in the presence of a candidate compound to subunit of the IL-3, IL-5 and GM-CSF receptors. Compounds that block the signalling pathways of the IL-3, IL-5 and GM-CSF receptors may be of use in the treatment of asthma.Type: GrantFiled: March 23, 1998Date of Patent: February 13, 2001Assignee: Pharmacia & Upjohn CompanyInventors: Steven L. Roberds, Paul S. Kaytes
-
Patent number: 6150330Abstract: Prolonged parenteral release into the circulatory system of a cow of a bioactive growth hormone releasing factor at desirably effective levels can be achieved using novel compositions in which the growth hormone releasing factor is present in an aqueous liquid at a dose of at least about 50 mg and at a concentration of at least about 20 mg/ml. Preferably, the growth hormone releasing factor is present in an aqueous liquid at a dose of about 200 mg and at a concentration of about 180 mg/ml. The aqueous bovine somatotropin formulation provides for the sustained release of bovine somatotropin into the circulatory system of the animal for greater than seven (7) days.Type: GrantFiled: December 13, 1996Date of Patent: November 21, 2000Assignee: Pharmacia & Upjohn CompanyInventors: Todd P. Foster, William M. Moseley, James F. Caputo, Michael J. Hageman